These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2128866)

  • 1. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W; Bimmermann A; Schleicher J
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
    Crepaldi G; Baggio G; Arca M; Avellone G; Avogaro P; Bittolo Bon G; Bompiani GD; Capurso A; Cattin L; D'Alŏ G
    Arch Intern Med; 1991 Jan; 151(1):146-52. PubMed ID: 1898694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
    Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP; Fonseca FA; Feres MC; da Silva RC; Lima JC; Martinez TL
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O; Angelin B; Fager G; Eriksson M; Olofsson SO; Berglund L; Lindén T; Sjöberg A; Bondjers G
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.